Managed Healthcare Executive September 8, 2025
Introduction
Bladder cancer is the sixth most common cancer in the United States with predictions of approximately 84,870 new cases and 17,420 deaths in 2025.1,2 Bladder cancer also has a high overall cost, approximately $4 to $5 billion spent annually in treatment and healthcare-related costs.3 Treatment, prognosis and management of bladder cancer is divided into three subtypes depending on the depth of bladder wall invasion and whether metastases are present: non-muscle invasive bladder cancer (NMIBC); muscle invasive, non-metastatic bladder cancer; and metastatic bladder cancer.4 NMIBC constitutes 75% of cases at diagnosis, and it has a favorable prognosis of greater than 70% survival at 10 years.4,5 Mainstay treatment for NMIBC includes resection of all visible disease, followed by intravesical chemotherapy.4 In...
Today's Sponsors
Today's Sponsor